Paying for the Oncotype DX Test
In the United States
All major insurance carriers cover the Oncotype DX test for eligible patients with early-stage invasive breast cancer. Medicare has established coverage for the Oncotype DX test for patients with DCIS (non-invasive) breast cancer, although coverage outside of Medicare will vary by insurance plan.
In the provinces of British Columbia, Alberta, Saskatchewan, New Brunswick, Ontario, Quebec, and Newfoundland, the test is publicly reimbursed on a case-by-case basis, meaning that doctors must seek prior approval for reimbursement before sending tissue to Genomic Health.
For insurance and financial-aid questions, please contact Genomic Health Customer Service: